# Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment

> **NCT02550106** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 136 (actual)

## Conditions studied

- CHRONIC SPONTANEOUS URTICARIA

## Interventions

- **DRUG:** OMALIZUMAB

## Key facts

- **NCT ID:** NCT02550106
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-22
- **Primary completion:** 2016-01-11
- **Final completion:** 2016-01-11
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02550106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02550106, "Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02550106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*